Human pharmacology of renzapride: a new gastrokinetic benzamide without dopamine antagonist properties

✍ Scribed by D. H. Staniforth; M. Pennick

• Book ID: 104692307
• Publisher: Springer
• Year: 1990
• Tongue: English
• Weight: 387 KB
• Volume: 38
• Category: Article
• ISSN: 0031-6970
• DOI: 10.1007/bf00265977

✦ Synopsis

The activity of the substituted benzamide renzapride on the upper gastrointestinal tract has been investigated. It has been shown to enhance stomach emptying in normal subjects; doses of 2 and 5 mg decreasing by 21 and 37% respectively the volume of gastric contents aspirated 80 min after a test meal. Renzapride was found to reduce the oro-caecal transit time as assessed by the lactulose/breath hydrogen method in a dose related manner from 0.2 to 5 mg; the later dose producing a 62% reduction. Finally renzapride was shown not to elevate plasma prolactin at a dose of 5 mg, a finding consistent with lack of dopamine receptor antagonism.